Strange: Bullish BMRN Analysts Actually See -1.6% Downside
June 23, 2020 at 09:24 AM EDT
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with BioMarin Pharmaceutical Inc (BMRN). The average 12-month price target for BMRN — averaging the work of 18 analysts — reveals an average price target of $120.39/share..